| 000 | 01783 a2200541 4500 | ||
|---|---|---|---|
| 005 | 20250515134820.0 | ||
| 264 | 0 | _c20081002 | |
| 008 | 200810s 0 0 cze d | ||
| 022 | _a0042-773X | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aPenka, M | |
| 245 | 0 | 0 |
_a[What is the current treatment of patients with essential thrombocytopenia and other myeloproliferations accompanied with thrombocythemia [corrected] and what can be the predictive sign of the risk of thrombosis in such patients--a report from the registry of patients treated by Thromboreductine]. _h[electronic resource] |
| 260 |
_bVnitrni lekarstvi _c |
||
| 300 |
_a775-82 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aFibrinolytic Agents _xadverse effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMyeloproliferative Disorders _xblood |
| 650 | 0 | 4 |
_aPlatelet Aggregation Inhibitors _xadverse effects |
| 650 | 0 | 4 | _aPlatelet Count |
| 650 | 0 | 4 |
_aQuinazolines _xadverse effects |
| 650 | 0 | 4 | _aRisk Assessment |
| 650 | 0 | 4 |
_aThrombocythemia, Essential _xblood |
| 650 | 0 | 4 |
_aThrombocytopenia _xcomplications |
| 650 | 0 | 4 |
_aThrombosis _xetiology |
| 700 | 1 | _aSchwarz, J | |
| 700 | 1 | _aPavlík, T | |
| 700 | 1 | _aPytiĺk, R | |
| 700 | 1 | _aDoubek, M | |
| 700 | 1 | _aDulícek, P | |
| 700 | 1 | _aKissová, J | |
| 700 | 1 | _aHlusi, A | |
| 700 | 1 | _aSchutzová, M | |
| 700 | 1 | _aCerná, O | |
| 700 | 1 | _aBrychtová, Y | |
| 700 | 1 | _aSzotkowski, T | |
| 700 | 1 | _aVolková, Z | |
| 700 | 1 | _aSeghetová, J | |
| 700 | 1 | _aVozobulová, V | |
| 700 | 1 | _aHadacová, I | |
| 700 | 1 | _aHochová, I | |
| 700 | 1 | _aVoglová, J | |
| 700 | 1 | _aDusek, L | |
| 773 | 0 |
_tVnitrni lekarstvi _gvol. 54 _gno. 7-8 _gp. 775-82 |
|
| 999 |
_c18249732 _d18249732 |
||